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Mendelian randomisation study of 
the relationship between vitamin D 
and risk of glioma
Hannah Takahashi1, Alex J. Cornish  1, Amit Sud  1, Philip J. Law  1, Ben Kinnersley  1,  
Quinn T. Ostrom2, Karim Labreche  1, Jeanette E. Eckel-Passow3, Georgina N. Armstrong4, 
Elizabeth B. Claus5,6, Dora ll’yasova  7,8,9, Joellen Schildkraut8,9, Jill S. Barnholtz-Sloan  2, 
Sara H. Olson10, Jonine L. Bernstein10, Rose K. Lai11, Minouk J. Schoemaker1,  
Matthias Simon12, Per Hoffmann13,14, Markus M. Nöthen14,15, Karl-Heinz Jöckel16,  
Stephen Chanock17, Preetha Rajaraman17, Christoffer Johansen  18, Robert B. Jenkins19, 
Beatrice S. Melin20, Margaret R. Wrensch21,22, Marc Sanson23,24, Melissa L. Bondy4,  
Clare Turnbull1,25,26 & Richard S. Houlston1,27
To examine for a causal relationship between vitamin D and glioma risk we performed an analysis 
of genetic variants associated with serum 25-hydroxyvitamin D (25(OH)D) levels using Mendelian 
randomisation (MR), an approach unaffected by biases from confounding. Two-sample MR was 
undertaken using genome-wide association study data. Single nucleotide polymorphisms (SNPs) 
associated with 25(OH)D levels were used as instrumental variables (IVs). We calculated MR estimates 
for the odds ratio (OR) for 25(OH)D levels with glioma using SNP-glioma estimates from 12,488 cases 
and 18,169 controls, using inverse-variance weighted (IVW) and maximum likelihood estimation (MLE) 
methods. A non-significant association between 25(OH)D levels and glioma risk was shown using 
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both the IVW (OR = 1.21, 95% confidence interval [CI] = 0.90–1.62, P = 0.201) and MLE (OR = 1.20, 
95% CI = 0.98–1.48, P = 0.083) methods. In an exploratory analysis of tumour subtype, an inverse 
relationship between 25(OH)D levels and glioblastoma (GBM) risk was identified using the MLE method 
(OR = 0.62, 95% CI = 0.43–0.89, P = 0.010), but not the IVW method (OR = 0.62, 95% CI = 0.37–1.04, 
P = 0.070). No statistically significant association was shown between 25(OH)D levels and non-GBM 
glioma. Our results do not provide evidence for a causal relationship between 25(OH)D levels and all 
forms of glioma risk. More evidence is required to explore the relationship between 25(OH)D levels and 
risk of GBM.
While glioma accounts for around 80% of malignant primary brain tumours1, thus far exposure to ionising radi-
ation is the only well-established exogenous risk factor2. Vitamin D provides many health benefits, including 
increased bone strength and protection against autoimmune diseases and type 2 diabetes3. In-vitro studies have 
also suggested an anti-neoplastic role for vitamin D4. Several epidemiological studies have shown that vitamin 
D may indeed afford protection against the development of some cancers, including colon, prostate and breast 
cancer5. Associations in such observational studies do not however constitute evidence for a causal relationship 
and in some studies bias from confounding and reverse causation cannot be excluded.
Mendelian randomisation (MR) uses genetic markers as proxies for environmental exposures to determine 
the effect of the exposure on disease risk6. It therefore provides a strategy for establishing causal relationships 
where randomised control trials (RCTs) would involve either high cost or impractical study design. In the case 
of a possible relationship between vitamin D and glioma, the rarity of the cancer would limit any RCT to small 
sample sizes and would require lengthy follow up times.
We implemented two-sample MR analysis to examine the relationship between vitamin D and glioma risk 
in order to avoid the limitations of follow up time, reverse causation and confounding. Genotypes are randomly 
assigned at conception, thereby limiting confounding. Furthermore an individual’s genotype will always be estab-
lished before the onset of disease, excluding the possibility of reverse causation. The genotype is in part equivalent 
to a lifetime vitamin D deficiency, and hence a lifetime follow-up time in a RCT. We determine the relationship 
between vitamin D and glioma risk using genetic variants associated with 25(OH)D levels, rather than measuring 
25(OH)D levels directly.
Genetic variants identified by the Study of Underlying Genetic Determinants of Vitamin D and Highly Related 
Traits (SUNLIGHT) Consortium7 and the Canadian Multicentre Osteoporosis Study (CaMOS)8 were used as 
an instrumental variable (IV). We performed an MR analysis to test for a causal relationship between 25(OH)
D levels and glioma, using summary data from a recent genome-wide association study (GWAS) meta-analysis 
performed by the Glioma International Case-Control Consortium (GICC)9.
Methods
Two-sample MR was undertaken using GWAS data. Ethical approval was not sought for this specific project 
because all data came from the summary statistics of previously published GWAS, and no individual-level data 
were used.
Genetic variant instruments for 25(OH)D level. Genetic variants used as IVs were selected from the 
previously published SUNLIGHT study7. The SUNLIGHT Consortium GWAS identified four genetic variants 
associated with lowered 25(OH)D levels in 33,996 individuals of European descent from 15 cohorts. These vari-
ants were rs2282679 in GC (vitamin D binding carrier protein), rs10741657 near CYP2R1 (converter of vitamin 
D to the active ligand for the vitamin D receptor), rs12785878 near DHCR7 (7-dehydrocholesterol synthesis from 
cholesterol, a precursor to vitamin D) and rs6013897 in CYP24A1 (degrader of active 1,25-dihydroxyvitamin 
D3 to inactive vitamin D)10. The roles of GC, CYP2R1, DHCR7 and CYP24A1 in the vitamin D pathway are 
shown in Fig. 1. Association estimates (per-allele log-ORs) for SNPs were taken from previously published stud-
ies, which used data from the CaMOS study, a population based cohort study of 2,347 Canadians, genotyped and 
assayed for 25(OH)D levels8,10,11. None of the SNPs were in linkage disequilibrium (i.e. r2 ≥ 0.001). For each SNP, 
we recovered the chromosome position, risk allele, genetic locus, F-statistic and association estimates (Table 1). 
Standard errors (SE) were calculated from F-statistics calculated by previous studies, which derive from the 
CaMOS cohort11. The risk allele was taken to be the 25(OH)D decreasing allele. Allele frequencies for these SNPs 
were compared between the 25(OH)D and glioma data sets to ensure that the effect estimates were recorded with 
respect to the same allele. This study calculated the variants to account for about 2% of the variation in circulating 
25(OH)D levels, and have a combined F-statistic of 12.5712.
Glioma genotyping data. Association data between the four genetic variants and glioma were taken from 
the most-recent meta-analysis of GWAS in glioma9, which related >10 million genetic variants (after imputa-
tion) to glioma (Supplementary Table 1). This meta-analysis comprised eight GWAS datasets of individuals of 
European descent: FRE, GER, GICC, MDA, GliomaScan (NIH), UCSF-Mayo, UCSF and UK (Supplementary 
Table 2). All diagnoses were confirmed in accordance with WHO guidelines. Full quality control details are pro-
vided in previously published work9. Gliomas are heterogeneous and different tumour subtypes, defined in part 
by malignancy grade (for example, pilocytic astrocytoma World Health Organization (WHO) grade I, diffuse 
‘low-grade’ glioma WHO grade II, anaplastic glioma WHO grade III and glioblastoma (GBM) WHO grade IV) 
can be distinguished13. To avoid diagnostic ambiguity and for simplicity we considered glioma subtypes as being 
either GBM or non-GBM.
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Statistical analyses. We examined the association between circulating 25(OH)D levels and glioma (includ-
ing subtypes) using MR on summary statistics using the inverse variance weighted (IVW) and maximum likeli-
hood estimation (MLE) methods, as described by Burgess et al.14. The combined ratio estimate (βˆ) of all SNPs 
associated with 25(OH)D levels on glioma risk was calculated under a fixed-effects model:
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Xk is the association between SNP k with 25(OH)D levels, Yk is the association between SNP k and glioma risk 
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We also conducted a likelihood based analysis using the same genetic summary data15. For this maximum 
likelihood estimate, a bivariate normal distribution for the genetic associations was assumed, and the R function 
optim was used to estimate β. SE β( ) was calculated using observed information.
With the estimates from the two analyses calculated for each of the eight cohorts in the glioma data, we 
performed a meta-analysis under a fixed-effect model to derive final odds ratios (ORs) and confidence intervals 
(CIs)16.
To test whether the variants chosen as instruments were valid under MR assumptions, we examined the 
instruments for pleiotropy (multiple traits influenced by one gene) between the exposure and disease risk. This 
would be revealed as deviation from a linear relationship between SNPs and their effect size for 25(OH)D levels 
and glioma risk. We performed MR-Egger regression to test the average pleiotropic effect caused by the vari-
ants combined, as well as to provide a third association estimate between 25(OH)D level and glioma17. As per 
Dimitrakopoulou et al.18, we further evaluated the presence of horizontal pleiotropy by conducting stratified MR 
analyses using only the genetic variants influencing vitamin D synthesis (rs12785878, rs10741657) and vitamin D 
metabolism (rs2282679, rs6013897). rs12785878 has been associated with non-European status10 and we there-
fore also undertook a sensitivity analysis excluding rs12785878.
For each statistical test, we considered a global significance level of P < 0.05 as being satisfactory to derive 
conclusions. To assess the robustness of our conclusions, we imposed a conservative Bonferroni-corrected signif-
icance threshold of 0.017 (i.e. 0.05/3 tumour classifications).
DHCR7
Cholecalciferol
Cholesterol
7-Dehydrocholesterol
25-hydroxylase
25(OH)D
1 -hydroxylase
1,25-dihydroxyvitamin D3
Inactivation of vitamin D
Cellular actions of vitamin D
KIDNEYS
LIVER
SUNLIGHT
CYP2R1
GC
CYP24A1
Figure 1. Effect of SNPs chosen as IVs on the vitamin D pathway. Genes that contain, or are in proximity to, 
variants chosen as IVs are highlighted green. P values for the association of these variants with 25(OH)D levels 
were 1.9 × 10−109 for GC, 2.1 × 10−27 for DHCR7, 3.3 × 10−20 for CYP2R1, and 6.0 × 10−10 for CYP24A1.
SNP ID Chr Locus
Base pair 
position
EA 
glioma
NEA 
glioma
EA 
25(OH)D
NEA 
25(OH)D
Effect on 
25(OH)D SE F-statistic
rs2282679 4 GC 72608383 G T G T −0.047 0.013 13.38
rs10741657 11 Near CYP2R1 14914878 G A G A −0.052 0.012 18.78
rs12785878 11 Near DHCR7 71167449 T G G T −0.056 0.013 18.29
rs6013897 20 CYP24A1 52742479 A T A T −0.027 0.015 3.13
Table 1. Genetic variant instruments for 25(OH)D levels. EA, effect allele; NEA, non-effect allele; SE, standard 
error. Positions given using NCBI build 37. EA taken to be the 25(OH)D decreasing allele. Effect taken to be the 
per allele log OR effect on 25(OH)D.
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The power of a MR investigation depends greatly on the proportion of variance in the risk factor that is 
explained by the IV. We therefore estimated study power to assess the strength of the results19. The detectable ORs 
at 80% power were 1.26 or 0.79 in the all glioma analysis, 1.34 or 0.75 in the GMB analysis and 1.35 or 0.74 in the 
non-GBM analysis. All power calculations were completed at a significance level of 0.05 and assumed the variants 
explained 2% of the total variance of 25(OH)D levels.
Data availability. Genotype data from the GICC GWAS are available from the database of Genotypes 
and Phenotypes (dbGaP; accession phs001319.v1.p1). Genotype data from the GliomaScan GWAS can also be 
accessed through dbGaP (accession phs000652.v1.p1). Data from the other studies are available upon request.
Results
The results of the IVW and MLE methods are summarised in Table 2. Results of the MR-Egger analysis are sum-
marised in Table 3. Forest plots of all results from the IVW and MLE methods are shown in Figs 2 and 3. There 
was no evidence to support an association (i.e. P > 0.05) between circulating 25(OH)D levels and risk of all gli-
oma using either the IVW (OR = 1.21, 95% CI = 0.90–1.62, P = 0.201) or MLE (OR = 1.20, 95% CI = 0.98–1.48, 
P = 0.083) methods. MR-Egger regression produced an intercept of −0.001 (95% CI = −0.019–0.017, P = 0.893) 
and therefore provided no evidence for pleiotropy amongst the genetic variants chosen as IVs (Supplementary 
Fig. 1). Hence there was no evidence of violation of MR assumptions.
We explored the possibility that a relationship between vitamin D and glioma may be subtype specific, con-
sidering GBM and non-GBM separately. We imposed a stronger significance threshold of P = 0.017 (i.e. 0.05/3), 
to correct for multiple testing. The MLE method identified an inverse relationship between 25(OH)D levels and 
risk of the GBM subtype, with an OR of 0.62 (95% CI = 0.43–0.89, P = 0.010). The IVW method provided a 
similar, but non-significant effect size (OR = 0.62, 95% CI = 0.37–1.04, P = 0.070). No evidence for an associa-
tion between 25(OH)D levels and the non-GBM subtype was identified using either the IVW or MLE methods. 
MR-Egger regression provided intercepts of −0.013 (95% CI = −0.039–0.012, P = 0.307) for GBM and −0.005 
(95% CI = −0.035–0.026, P = 0.768) for non-GBM, again providing no evidence of pleiotropy.
Stratified MR analyses using separate allelic scores for vitamin D synthesis and metabolism did not indicate 
the presence of horizontal pleiotropy (Supplementary Tables 3 and 4). To address the potential effects of popula-
tion stratification, we undertook a MR sensitivity analysis excluding rs12785878, as this SNP has been associated 
with non-European status10 (Supplementary Table 5). Excluding rs12785878, the inverse relationship between 
25(OH)D levels and risk of the GBM subtype identified by the MLE method remains significant (OR = 0.51, 
95% CI = 0.33–0.80, P = 0.003), thereby providing no evidence that this association is a result of population 
stratification.
Discussion
To our knowledge, this is the first MR study evaluating the effect of vitamin D on glioma risk undertaken. Overall 
our results do not provide evidence for an effect of vitamin D on risk of all forms of glioma. They do however raise 
the possibility for a protective role of vitamin D in GBM. While vitamin D and its metabolites have been shown to 
induce death of glioblastoma cells20–22, only one epidemiological study has investigated the relationship between 
pre-diagnostic levels of 25(OH)D and glioma risk23. Researchers found that higher levels of 25(OH)D were pro-
tective against high-grade glioma in men over the age of 56 (OR = 0.59), although the reverse trend was shown 
in men under the age of 56, albeit at a borderline-significant level23. Excluding the possibility of post hoc data 
mining, such paradoxical findings would support distinct aetiologies between the GBM and non-GBM subtypes, 
as has been suggested previously9.
IVW method MLE method
β SE(β) OR (95% CI) P value β SE(β) OR (95% CI) P value
All glioma 0.189 0.148 1.21 (0.90–1.62) 0.201 0.184 0.106 1.20 (0.98–1.48) 0.083
GBM −0.471 0.261 0.62 (0.37–1.04) 0.070 −0.479 0.186 0.62 (0.43–0.89) 0.010
Non-GBM 0.177 0.281 1.19 (0.69–2.07) 0.529 0.177 0.199 1.19 (0.81–1.76) 0.373
Table 2. MR estimates between multi-SNP risk scores of 25(OH)D levels and all glioma, GBM and non-
GBM glioma using the IVW and MLE methods. IVW, inverse-variance weighted; MLE, maximum likelihood 
estimation; SE, standard error; OR, odds ratio; CI, confidence interval; GBM, glioblastoma.
MR Egger slope MR Egger intercept
Estimate (95% CI) P value Estimate (95% CI) P value
All Glioma 0.072 (−0.121–0.264) 0.466 −0.001 (−0.019–0.017) 0.893
GBM −0.097 (−0.272–0.078) 0.279 −0.013 (−0.039–0.012) 0.307
Non-GBM 0.160 (−0.114–0.434) 0.253 −0.005 (−0.035–0.026) 0.768
Table 3. MR-Egger test results for 25(OH)D levels and all glioma, GBM and non-GBM glioma. CI, confidence 
interval; GBM, glioblastoma.
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Vital to the method of statistical analysis used herein is that none of the MR assumptions are violated. This 
requires that the variants chosen as IVs are (i) strongly associated with the exposure, (ii) are not associated with 
any confounding effects between exposure and outcome and (iii) are only associated with the outcome via the 
exposure. With regard to this study, the instruments chosen were associated with 25(OH)D levels at genome-wide 
significance levels. The MR-Egger test provided no evidence of horizontal pleiotropy, which we deemed suf-
ficient to satisfy the third assumption. Furthermore, none of the four SNPs were in linkage disequilibrium 
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Figure 2. Individual cohort and meta-analysis ORs calculated using the IVW method. (a) All glioma, (b) 
GBM and (c) non-GBM glioma. Boxes are OR point estimates with area proportional to the weight of the 
study. Diamonds are overall summary estimates, with 95% CIs given by the width. Vertical line is null value 
(OR = 1.0).
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(i.e. r2 ≥ 0.001) with any of the variants identified by Melin et al.9 as being in the risk region for glioma. With 
regard to confounding factors, few risk factors are known for glioma, so it was not possible to entirely rule out the 
possibility of unknown confounding factors causing statistical bias. However it should also be noted that all four 
SNPs lie either within or near genetic loci whose function in vitamin D physiology is well understood7, although 
a lack of knowledge of possible confounding factors means it was not possible to entirely rule out the possibility 
of confounding by unknown factors.
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Figure 3. Individual cohort and meta-analysis ORs calculated using the MLE method. (a) All glioma, (b) 
GBM and (c) non-GBM glioma. Boxes are OR point estimates with area proportional to the weight of the 
study. Diamonds are overall summary estimates, with 95% CIs given by the width. Vertical line is null value 
(OR = 1.0).
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We acknowledge that a weakness of our study was in the small percentage of variability (around 2%) in 
25(OH)D levels explained by the IV. Such a low value means any interpretation of these results as true indicators 
of the effect of total 25(OH)D levels on glioma risk are limited. This is quantified by the high ORs required for suf-
ficient study power. Furthermore the study only accounts for circulating 25(OH)D levels and not for the action of 
25(OH)D at the cellular level11. The genetic variants used as IVs in this MR analysis associate with 25(OH)D lev-
els, rather than levels of the biologically active 1,25-dihydroxyvitamin D (1,25(OH)2D) and we therefore cannot 
explicitly comment on the relationship between 1,25(OH)2D and glioma. The low OR found in the GBM analysis 
should be noted however, given the fairly consistent indications of protective effects of 25(OH)D across all three 
methods. As is generally the case with MR, any findings should be viewed as a compliment to other future epi-
demiological studies, which test more robustly for associations between vitamin D and glioma and its subtypes.
In conclusion our MR analysis provides no evidence for an association between vitamin D and glioma, 
though findings raise the possibility of a potential association between vitamin D and GBM warranting further 
investigation.
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